BPC
SUPN icon

Bryce Point Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Bryce Point Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$269K Buy
+5,619
New +$226K 0.33% 146

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bryce Point Capital's SUPN Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Supernus Pharmaceuticals (SUPN) in Q3 2025: 5,619 shares worth $269K. The stake represents 0.33% of the portfolio and ranks #146 among its holdings.

310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Bryce Point Capital held 5,619 shares of Supernus Pharmaceuticals worth $269K as of Q3 2025.
  • Supernus Pharmaceuticals was a new Bryce Point Capital position in Q3 2025.
  • Supernus Pharmaceuticals made up 0.33% of Bryce Point Capital's portfolio in Q3 2025, its #146 holding.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.